Dr Adrian Minson awarded Fellowship to continue lymphoma research
20 February 2026
Peter Mac clinical researcher Dr Adrian Minson has had his Snowdome Foundation fellowship extended, allowing him to develop world leading research into immunotherapy treatment for aggressive B-cell lymphomas.
Since receiving the first Snowdome Fellowship in 2024, Dr Minson has developed and implemented four investigator-initiated clinical trials aimed at improving outcomes for high-risk lymphoma patients, opened industry-sponsored trials of first-in-human immunotherapy treatments, and provided options of novel immunotherapies for over 200 Australians.
Dr Minson said one of the most impressive trial results was observed in the COALITION trial, which reported no evidence of disease progression at two years in 86 percent of patients with high-risk lymphoma treated with a novel immunotherapy treatment.
“This result is significant given that the expected outcome with standard treatments is closer to 50 per cent. The research represents a possible paradigm shift in the treatment of aggressive lymphomas,” he said.
“The results of this trial were presented at a major International Haematology Meeting and support us conducting other trials in larger groups of patients.
“The Fellowship will allow me dedicated time to focus on this trial, collate biomarker samples, and link clinical findings with laboratory and translational research findings.
“Our goal is to establish a new global standard of care for high-risk lymphoma patients.”
Snowdome’s Chief Executive, Vincent Ramos, said, “As the 2024 Snowdome Fellow, Dr Minson, under the guidance of Professor Michael Dickinson, has made remarkable progress in improving outcomes for lymphoma patients, and we are proud to continue supporting this groundbreaking research.”